|
|
Article: Forest Laboratories, Inc. - Deutsche Bank Securities Inc.'s David Steinberg Initiates Research Coverage.
- Article from:
- PR Newswire
- Article date:
- April 2, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Deutsche Bank Securities Inc. analyst David Steinberg expanded coverage of the Specialty Pharmaceuticals sector by initiating coverage this morning of Forest Laboratories, Inc. ($81.40) with a BUY investment rating. Forest Laboratories has established itself as the leading worldwide specialty pharmaceutical company both in terms of product sales and market capitalization, driven by the success of its antidepressant Celexa.
According to Steinberg, the company now stands on the cusp of launching its next major growth driver, the next generation antidepressant Lexapro. Steinberg believes Lexapro has peak sales potential of $2 billion based on a strong ...